A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma Journal Article
| Authors: | Palomba, M. L.; Ghione, P.; Patel, A. R.; Nahas, M.; Beygi, S.; Hatswell, A. J.; Kanters, S.; Limbrick-Oldfield, E. H.; Wade, S. W.; Ray, M. D.; Owen, J.; Neelapu, S. S.; Gribben, J.; Radford, J.; Bobillo, S. |
| Article Title: | A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma |
| Abstract: | Background: In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority relative to the SCHOLAR-5 external control cohort. We update this comparison using the ZUMA-5 24-month data. Research design and methods: The SCHOLAR-5 cohort is comprised of r/r FL patients who initiated ≥3rd line of therapy after July 2014 and meeting ZUMA-5 eligibility criteria. Groups were balanced for patient characteristics through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. The overall response rate was compared using a weighted logistic regression. Time-to-event outcomes were evaluated using a Cox regression. Results: For SCHOLAR-5, the sum of weights for the 143 patients was 85 after SMR weighting, versus 86 patients in ZUMA-5. The median follow-up was 29.4 months and 25.4 months for ZUMA-5 and SCHOLAR-5, respectively. The hazard ratios for overall survival and progression-free survival were 0.52 (95% confidence interval (CI): 0.28–0.95) and 0.28 (95% CI: 0.17–0.45), favoring axi-cel. Conclusion: This updated analysis, using a longer minimum follow-up than a previously published analysis, shows that the improved efficacy of axi-cel, relative to available therapies, in r/r FL is durable. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; cancer survival; controlled study; major clinical study; overall survival; drug efficacy; cancer patient; follow up; progression free survival; cohort analysis; pathology; lymphoma, large b-cell, diffuse; follicular lymphoma; lymphoma, follicular; adoptive immunotherapy; immunotherapy, adoptive; biological product; biological products; progression-free survival; comparative effectiveness; clinical outcome; diffuse large b cell lymphoma; cancer prognosis; propensity score analysis; humans; human; male; female; article; standardized mortality ratio; axicabtagene ciloleucel; zuma-5 |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 23 |
| Issue: | 2 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2023-01-01 |
| Start Page: | 199 |
| End Page: | 206 |
| Language: | English |
| DOI: | 10.1080/14737140.2023.2171994 |
| PUBMED: | 36723678 |
| PROVIDER: | scopus |
| PMCID: | PMC11104735 |
| DOI/URL: | |
| Notes: | Article -- MSK corresponding author is M. Palomba -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work